Vorasidenib Reduces Risk of Progression/Death in Low-Grade Glioma

Vorasidenib (AG-881), an IDH1/2 inhibitor, yielded a reduction in risk of progression of death of 61% vs matched placebo in a population of patients diagnosed with low-grade IDH-mutant glioma, according to data from the phase 3, double-blind INDIGO trial (NCT04164901) that were shown during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.^1,2

In the study, 331 patients with IDH-mutant low-grade glioma were randomized to receive oral vorasidenib at 40 mg once daily or matched placebo in 28-day cycles.

Median independently assessed imaging-based progression-free survival (PFS) with vorasidenib was 27.7 months (95% CI, 17.0-not estimated) compared with 11.1 months (95% CI, 11.0-13.7) for those treated with placebo (HR, 0.39; 95% CI, 0.27-0.56; P <.001). Treatment in the study was given during a “watch and wait” period used to delay the start of debilitating chemoradiation therapy, which is standard following glioma resection. In addition to improvements in PFS, vorasidenib also resulted in a significant lengthening in the interval to receipt of another treatment (HR, 0.26; 95% CI, 0.15-0.43; P <.001).

“Our study shows that targeting IDH mutations with vorasidenib significantly delays tumor growth and the need for more toxic therapies,” lead author Ingo Mellinghoff, MD, FACP, of Memorial Sloan Kettering Cancer Center, said in a statement. “This is clinically meaningful because patients diagnosed with grade 2 glioma with IDH mutations are typically young, otherwise healthy individuals. The results of this trial offer a chance to change the treatment paradigm for this type of glioma and could bring the first new targeted therapy for low-grade glioma.”

In the study, 331 patients were randomized to receive oral vorasidenib (n = 168) at 40 mg once daily or matched placebo (n = 163) in 28-day cycles. The median age of patients in the vorasidenib arm was 40.5 years vs 39.0 years in the control arm. North America was the most common geographic region, at 51.2% and 65.6% for the investigational and control arms, respectively. Additional locations included Western Europe and Israel. Approximately half of patients in each arm had a Karnofsky performance status of 100 (53.6% and 53.4%, for vorasidenib and placebo, respectively).

Histologic subtypes of low-grade glioma were evenly distributed between oligodendroglioma and astrocytoma. The location of the tumor at primary diagnosis was frontal for two-thirds of patients. The longest diameter of tumor was 2 or more centimeters for most patients (82.7% vs 84.0%, for vorasidenib and placebo, respectively). The median interval from last glioma surgery to randomization was 2.4 years and 21.5% had received 2 or more tumor surgeries before enrollment.

All patients were positive for an IDH mutation, with the majority having an IDH1 alteration, which was present in 97% of those in the vorasidenib arm and for 93.3% in the placebo group. More than half of patients also had a codeletion in chromosome 1p/19q.

The median follow-up was 14.0 months (interquartile range [IQR], 10.1-17.9) for vorasidenib and was 14.3 months (IQR, 10.0-18.1) for placebo. Imaging-based progression determined by a blinded independent review occurred in 28% of those in the vorasidenib arm compared with 54% for those in the placebo group. Investigator-assessed results were similar to those reported in the primary analysis, with vorasidenib remaining superior (HR, 0.35; 95% CI, 0.23-0.54).

There was an 85.6% (95% CI, 77.8%-90.8%) likelihood of not requiring another intervention at 18 months in the vorasidenib arm compared with 47.4% (95% CI, 35.8%-58.2%) in the placebo arm. At the 24-month assessment, 83.4% (95% CI, 74.0%-89.6%) of patients in the vorasidenib arm still had not required another intervention compared with 27.0% (95% CI, 7.9%-50.8%) in the placebo group. Following initial results, the study was unblinded and patients were allowed to cross over. There were 52 patients initially in the placebo arm (31.9%) who crossed over to receive vorasidenib.

“Second interim analysis was so clear and showed efficacy so clearly that the data monitoring board recommended that we unblind,” Mellinghoff noted.

The 18-month PFS rate was 60.4% (95% CI, 48.3%-70.5%) in the vorasidenib arm compared with 26.7% (95% CI, 17.1%-37.4%) in the placebo arm. The 24-month PFS rates were 50.7% (95% CI, 36.2%-63.5%) in the vorasidenib arm compared with 17.6% (95% CI, 7.1%-31.9%) in the placebo arm.

The objective response rate (ORR) was 10.7% (95% CI, 6.5%-16.4%) with vorasidenib compared with 2.5% (95% CI, 0.7%-6.2%) for placebo (odds ratio, 4.88; 95% CI, 1.56%-15.25%). In the vorasidenib arm, this included 2 partial responses (1.2%) and 16 minor responses (9.5%). The placebo arm was all minor responses. Most patients had stable disease, with progressive disease seen in 6.0% and 8.6% of those in the vorasidenib and placebo arms, respectively.

An ASCO Expert commenting on the results, Glenn Lesser, MD, FASCO, said “These results are quite striking and they’re statistically highly significant, and more important, they’re clinically very important. In select patients with low-grade glioma, we can potentially delay the use of these toxic chemotherapy and radiation for years, perhaps many years, and delay the toxicity.”

An adverse effect (AEs) of any grade occurred in 94.6% of those in the vorasidenib group and for 93.3% of those in the placebo arm. Grade 3 or higher AEs occurred in 22.8% of patients in the vorasidenib arm compared with 13.5% of those in the placebo arm. The most common AEs in the vorasidenib arm were related to liver enzyme increases, including increases in alanine aminotransferase (ALT; 38.9%; 9.6% was grade 3 or higher), aspartate aminotransferase (AST; 28.7%; 4.2%), and gamma-glutamyl transferase (GGT; 15.6%; 3.0%).

There were 3 serious AEs reported in the vorasidenib arm that were reported to be associated with the treatment, specifically ALT increase, hepatic failure, and hepatitis. All serious AEs were considered resolved at the time of the analysis in September 2022. AEs led to discontinuation for 3.6% of patients in the vorasidenib arm compared with 1.2% in the placebo arm. Dose reductions were needed for 10.8% of those in the vorasidenib arm compared with 3.1% in the placebo group. Dose interruptions occurred for approximately one-quarter of patients in both arms.

References

1. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. Published online June 4, 2023. doi:10.1056/NEJMoa2304194
2. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. J Clin Oncol. 2023;41(suppl 17):LBA1. doi:10.1200/JCO.2023.41.17_suppl.LBA1